Semaglutide brands
Weight-loss treatment comparison usually starts with route families: injections, tablets, capsules, NHS access, private providers and broader support models. The right comparison depends on whether you are choosing a treatment route, a provider service or an access pathway.
Treatment names sit inside wider care routes
Named medicines matter, but they are only one part of the comparison. Assessment, route type, dose or pack basis, support, delivery and provider responsibility all affect how a treatment route feels in practice.
Start here before opening the main treatment sections. If you already know the route you want to compare, the injection and tablet hubs are usually the clearest next step. If you are still deciding between NHS, private and online provider routes, compare access and eligibility first.
Injection routes
Mounjaro and Wegovy are usually compared by weekly route, dose context, checks and provider support.
Tablet and capsule routes
Orlistat, Xenical, Mysimba, Alli and Orlos are usually compared by active ingredient, pack or strength, checks and guidance.
Access and service routes
NHS, private, online pharmacy, online doctor and programme-led routes can change assessment and support expectations.
Start with the question you need answered
If your main question is about treatment type, compare injections and tablets first. If your main question is about price, look at dose, pack size, delivery and repeat-cost context together. If your main question is safety or suitability, start with eligibility and provider legitimacy before opening a provider website.
Prices, availability and provider checks can change. The comparison pages are designed to show useful context and reviewed dates, but they do not replace a clinical assessment or current information from the provider.
Important information
This website is an informational comparison hub. It does not prescribe, supply or sell prescription-only medicines. Suitability depends on a regulated clinical assessment.
Some links may be affiliate or commercial links. Commercial relationships must not change the way safety, eligibility, source checks or editorial context are presented.
Next step
Keep the semaglutide route and brand context connected
Keep the ingredient guide, the brand comparisons and the provider evidence connected as you move through the site.